Research

Cellular

Tirzepatide is linked to a significantly reduced risk of overall hematologic malignancy (OR = 0.14, 95%CI = 0.03-0.60), particularly for lymphoma.

Tirzepatide may be a safer option for patients concerned about hematologic malignancies.

StrongSupportsmedium confidence
In contrast, tirzepatide was linked to a significantly reduced risk (OR = 0.14, 95%CI = 0.03-0.60), especially for lymphoma.
Pao‐Yen Lin et al. · Biomolecules · 2025

Why this rating

Based on a pilot network meta-analysis of randomized controlled trials.

Source

Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis

Pao‐Yen Lin et al. · Biomolecules · 2025

DOI 10.3390/biom15111622

Meta-analysisCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →